Seres Therapeutics, Inc.MCRBNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank79
5Y CAGR-19.3%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
-19.3%/yr
Long-term compound
Percentile
P79
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
5 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 13.79% |
| Q3 2025 | 9.66% |
| Q2 2025 | 8.65% |
| Q1 2025 | 5.55% |
| Q4 2024 | 1.15% |
| Q3 2024 | -1.04% |
| Q2 2024 | 16.17% |
| Q1 2024 | 12.87% |
| Q4 2023 | 11.35% |
| Q3 2023 | -190.03% |
| Q2 2023 | 170.18% |
| Q1 2023 | -3.31% |
| Q4 2022 | -15.56% |
| Q3 2022 | 6.66% |
| Q2 2022 | -13.59% |
| Q1 2022 | -12.78% |
| Q4 2021 | -172.26% |
| Q3 2021 | 242.09% |
| Q2 2021 | -36.28% |
| Q1 2021 | -97.37% |
| Q4 2020 | 40.33% |
| Q3 2020 | -46.00% |
| Q2 2020 | -4.33% |
| Q1 2020 | -2.61% |
| Q4 2019 | -11.69% |
| Q3 2019 | -56.95% |
| Q2 2019 | 55.41% |
| Q1 2019 | -13.30% |
| Q4 2018 | 2.43% |
| Q3 2018 | 21.06% |
| Q2 2018 | 0.46% |
| Q1 2018 | 5.07% |
| Q4 2017 | -307.10% |
| Q3 2017 | 74.26% |
| Q2 2017 | -9.76% |
| Q1 2017 | -0.85% |
| Q4 2016 | -34.45% |
| Q3 2016 | 32.14% |
| Q2 2016 | -41.29% |
| Q1 2016 | -0.65% |